Why Tonix Pharmaceuticals Stock Is Rocketing Higher Today

Tonix Pharmaceuticals Holding Corp TNXP shares are trading higher Monday after the company announced the exclusive license of potential therapeutic or preventative humanized anti-SARS-CoV-2 monoclonal antibodies from Curia Global.

What Happened: Tonix obtained an exclusive license from Curia Global for the development of three humanized murine monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection, which causes COVID-19.

"The Company believes that murine monoclonal antibodies have the potential for neutralizing a broader spectrum of SARS-CoV-2 variants and may be harder for SARS-CoV-2 to evade as we face a ‘variant soup' from both convergent and divergent evolution," said Seth Lederman, CEO of Tonix.

The murine monoclonal antibodies and their humanized counterparts build on a base of knowledge from the company's fully human monoclonal antibody platform, TNX-3600.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.

See Also: Alibaba, Nio Stocks Drop: Hang Seng Opens Weaker As US Inflation Data, Fed Meet Eyed

TNXP Price Action: Tonix has a 52-week high of $14.08 and a 52-week low of 35 cents per share.

The stock was up 82.7% at 67 cents at time of publication, according to Benzinga Pro.

Photo: Masum Ali from Pixabay.